Elgie A W, Sargent J M, Taylor C G, Williamson C
Haematology Research Department, Pembury Hospital, Kent, U.K.
Leuk Res. 1996 May;20(5):407-13. doi: 10.1016/0145-2126(95)00163-8.
We have utilized the MTT assay to measure the metabolic activity of cells from the bone marrow of 55 patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and non-clonal disease. Doubling dilutions of cells were exposed to MTT for 3-4 h. The mean optical density of the formazan produced by each cell dilution was plotted and the gradient of the line produced was calculated, higher gradients indicating more metabolically active cells. Results showed that the median activity of mononuclear cells from seven patients with non-clonal disease was 0.202 (range 0.175-0.253); blast cells from 27 patients with de novo AML had a median activity of 0.187 (range 0.079-0.345) and 13 patients with MDS a median of 0.155 (range 0.062-0.311). Seven assays on mononuclear cells from five patients in remission had a median activity of 0.203 (range 0.190-0.248), indicating no significant difference between these and normal patients. There was no correlation between the metabolic activity of cells when compared with their proliferative capacity, cell size and expression of P-glycoprotein. Following exposure of the AML patients' blast cells to the anthracyclines, cytosine arabinoside, 6-thioguanine and etoposide, cell survival was measured using the MTT assay. While there was no correlation between the in vitro sensitivity of these cells to the anthracyclines or etoposide, less metabolically active cells showed significantly greater sensitivity to 6-thioguanine. Conversely, the more active cells appeared to be more sensitive to cytosine arabinoside. Patients whose blasts cells showed higher metabolic activity appeared to achieve remission and had a longer mean survival time. Therefore, by using a simple technique we were able to establish that some patients were more likely to respond to certain cytotoxic regimes. Our preliminary study reflected the multifactorial nature of clinical response in AML and MDS, so providing further information on the relationship between cellular metabolic activity and treatment failure.
我们运用MTT法检测了55例急性髓系白血病(AML)、骨髓增生异常综合征(MDS)及非克隆性疾病患者骨髓细胞的代谢活性。将细胞进行双倍稀释后,使其与MTT接触3 - 4小时。绘制每个细胞稀释度产生的甲臜的平均光密度,并计算所得直线的斜率,斜率越高表明细胞代谢活性越高。结果显示,7例非克隆性疾病患者的单核细胞活性中位数为0.202(范围0.175 - 0.253);27例初发AML患者的原始细胞活性中位数为0.187(范围0.079 - 0.345),13例MDS患者的原始细胞活性中位数为0.155(范围0.062 - 0.311)。对5例缓解期患者的单核细胞进行的7次检测,活性中位数为0.203(范围0.190 - 0.248),表明这些患者与正常患者之间无显著差异。细胞的代谢活性与其增殖能力、细胞大小及P - 糖蛋白表达之间无相关性。将AML患者的原始细胞暴露于蒽环类药物、阿糖胞苷、6 - 硫鸟嘌呤及依托泊苷后,用MTT法检测细胞存活率。虽然这些细胞对蒽环类药物或依托泊苷的体外敏感性之间无相关性,但代谢活性较低的细胞对6 - 硫鸟嘌呤显示出显著更高的敏感性。相反,活性较高的细胞似乎对阿糖胞苷更敏感。原始细胞代谢活性较高的患者似乎更易达到缓解,且平均生存时间更长。因此,通过使用一种简单技术,我们能够确定一些患者更有可能对某些细胞毒性方案产生反应。我们的初步研究反映了AML和MDS临床反应的多因素性质,从而提供了关于细胞代谢活性与治疗失败之间关系的更多信息。